Nicorandil-induced hyperkalemia in a uremic patient

Case Reports in Medicine

Volumn 2012, Issue , 2012, Pages

  Lee, Hung Hao ^a   Hsu, Po Chao ^a   Lin, Tsung Hsien ^a,b   Lai, Wen Ter ^a,b   Sheu, Sheng Hsiung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NICORANDIL; POTASSIUM;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BRADYCARDIA; CASE REPORT; CORONARY ARTERY OBSTRUCTION; ELECTROCARDIOGRAM; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MALE; PERCUTANEOUS CORONARY INTERVENTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; UREMIA;

EID: 84936983298     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2012/812178     Document Type: Article

References (14)

1. Knight C., Purcell H., Fox K., Potassium channel openers: clinical applications in ischemic heart disease-overview of clinical efficacy of nicorandil. Cardiovascular Drugs and Therapy 1995 9 2 229 236 2-s2.0-0029058468
2. Singer M., Coluzzi F., O'Brien A., Clapp L. H., Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. The Lancet 2005 365 9474 1873 1875 2-s2.0-19744369012 10.1016/S0140-6736(05)66619-6 (Pubitemid 40744965)
3. Quayle J. M., Nelson M. T., Standen N. B., ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiological Reviews 1997 77 4 1165 1232 2-s2.0-0030772859 (Pubitemid 27459582)
4. Gross G. J., Peart J. N., K ATP channels and myocardial preconditioning: an update. American Journal of Physiology 2003 285 3 H921 H930 2-s2.0-0042360198 (Pubitemid 37048144)
5. + channel openers: old drugs with new clinical benefits for the heart. Current Vascular Pharmacology 2003 1 3 251 258 2-s2.0-14844295592
6. IONA Study Group, Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. The Lancet 2002 359 9314 1269 1275 2-s2.0-0037070736 10.1016/S0140-6736(02) 08265-X (Pubitemid 34310631)
7. Roland E., Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. European Heart Journal 1993 14 Supplement B 48 52 2-s2.0-0027325609 (Pubitemid 23233991)
8. Krumenacker M., Roland E., Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. Journal of Cardiovascular Pharmacology 1992 20 Supplement 2 S93 S102 2-s2.0-0026669804
9. Arnold J. M. O., Kowey P. R., Wolf D. L., Jungbluth G. L., Hearron A. E., Luderer J. R., Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain. International Journal of Cardiology 1994 44 3 203 205 2-s2.0-0028279490 10.1016/0167-5273(94)90284-4
10. Dunn N., Freemantle S., Pearce G., Wilton L. V., Mann R. D., Safety profile of nicorandil-prescription-event monitoring (PEM) study. Pharmacoepidemiol Drug Safety 1999 8 197 205 (Pubitemid 29286532)
11. Montgomery H., Sumeray M., Carr C., Singer M., Sinus arrest and severe peripheral vasodilation following cardiopulmonary bypass in a patient taking nicorandil. Cardiovascular Drugs and Therapy 1997 11 1, article 81 2-s2.0-0030904986 10.1023/A:1007764210280 (Pubitemid 27153563)
12. Del Canale S., Fiaccadori E., Ronda N., Muscle energy metabolism in uremia. Metabolism: clinical and Experimental 1986 35 11 981 983 2-s2.0-0023039010 (Pubitemid 17186298)
13. Molinaro M., Villa G., Regazzi M. B., Salvadeo A., Segagni S., Rondanelli R., Sartirana E., Pharmacokinetics of nicorandil in patients with normal and impaired renal function. European Journal of Clinical Pharmacology 1992 42 2 203 207 2-s2.0-0026537049
14. Frydman A., Pharmacokinetic profile of nicorandil in humans: an overview. Journal of Cardiovascular Pharmacology 1992 20 3 S34 S44 2-s2.0-0026737306